Vir, WuXi collaborating on COVID-19 mAbs

Vir and WuXi Biologics announced Tuesday a collaboration to develop and manufacture mAbs to treat COVID-19. The partnership combines Vir’s mAb discovery engine with WuXi’s development and manufacturing muscle.

Working with samples from patients who had survived infection with SARS, Vir Biotechnology Inc. (NASDAQ:VIR) said it has “identified a number of monoclonal antibodies that bind to SARS-CoV-2,” the virus that causes COVID-19. Vir is conducting research to determine if the mAbs from the closely related SARS, or additional antibodies it may identify, “can be effective as treatment and/or prophylaxis against SARS-CoV-2.”

WuXi Biologics Inc. (HKEX:2269) will be responsible for cell-line development, process and formulation development, and initial manufacturing for clinical development. The deal gives WuXi Biologics commercialization rights in Greater China. Vir will have rights to commercialize any approved products in all other markets worldwide.

Vir gained $2.77 (15%) to $21.73 on Tuesday.

Further analysis of the coronavirus crisis can be found at The COVID-19 content is free to all who visit the site.

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers